RASGEF1B

Across TCGA pan-cancer cohorts, RASGEF1B mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RASGEF1B’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where RASGEF1B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RASGEF1B is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC and LUAD are the cancer types where RASGEF1B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RASGEF1B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	−0.501	<.001	4	view →
LUAD	All	All	−0.372	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

RASGEF1B–LSCC

Open the LSCC breakdown →